- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04907539
A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
A Multi-arm, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy of RXC004 in Monotherapy and in Combination With Nivolumab, in Patients With Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer Who Have Progressed Following Therapy With Current Standard of Care (PORCUPINE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is composed of two arms, RXC004 monotherapy (Arm A) and RXC004 in combination with nivolumab (Arm B). 20 evaluable patients will be enrolled in Arm A and 20 eligible patients in Arm B.
The study initially opened with Arm A; Arm B will be opened once a recommended Phase II dose (RP2D) for RXC004 in combination with nivolumab is established in the phase I dose escalation study (NCT03447470).
Once Arm B is opened, patients who are eligible for both Arm A and Arm B will be randomised 2:1 to Arm B: Arm A in an open-label manner.
Patients in Arm A may be treated with RXC004 + nivolumab if they have progressive disease on the 8 week scan, as long as they are eligible for Arm B and have Sponsor approval.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 5505
- Asan Medical Center - Oncology
-
Seoul, Korea, Republic of, 3722
- Severance Hospital, Yonsei University Health System - Medical Oncology
-
Seoul, Korea, Republic of, 6351
- Samsung Medical Center - Hematology-Oncology
-
-
Gyeonggido [Kyonggi-do]
-
Goyang-si, Gyeonggido [Kyonggi-do], Korea, Republic of, 10408
- National Cancer Center
-
-
-
-
-
Barcelona, Spain, 08003
- Hospital del Mar
-
Barcelona, Spain, 08036
- Hospital Clinic de Barcelona
-
Barcelona, Spain, 08035
- Hospital Universitario Vall d'Hebron
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
Sevilla, Spain, 41013
- Hospital Universitario Virgen del Rocio
-
-
-
-
-
Birmingham, United Kingdom, B152TH
- Queen Elizabeth Hospital - Clinical Reasearch
-
London, United Kingdom, SW3 6JJ
- The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital
-
London, United Kingdom, NW1 2PG
- University College of London (UCL)
-
Manchester, United Kingdom, CB2 0QQ
- Christie Hospital
-
Oxford, United Kingdom, OX3 7LJ
- Oxford Cancer Centre
-
Surrey Quays, United Kingdom, SM25PT
- The Royal Marsden Hospital (Surrey)
-
-
Scotland
-
Glasgow, Scotland, United Kingdom, G12 0YN
- Beatson West of Scotland Cancer Centre - Oncology
-
-
-
-
California
-
Santa Rosa, California, United States, 95403
- Providence Medical Foundation
-
-
Indiana
-
Indianapolis, Indiana, United States, 46250
- Community Health Network Cancer Center North - Community Hospital Network
-
-
Nevada
-
Las Vegas, Nevada, United States, 89102
- OptumCare Cancer Care
-
-
Texas
-
Houston, Texas, United States, 77030-4000
- UT MD Anderson Cancer Center
-
Kingswood, Texas, United States, 77339
- Lumi Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Histological documentation of metastatic (Stage IV) Colorectal cancer (CRC) and
- Documented tumour tissue aberration in RNF43 and/or RSPO
- Documented confirmation of microsatellite stable (MSS) status
- Patients must have had documented radiological progression following a minimum of 1 prior SOC treatment regimen for metastatic disease
- Eastern Cooperative Oncology Group performance status 0 or 1
- At least one lesion that is measurable by RECIST 1.1 at baseline
- Patients must have at least one lesion suitable for biopsy at screening and be willing to provide mandatory tumour biopsy samples
- Patients with adequate organ functions
- Female patients of childbearing potential must have a negative pregnancy test prior to start of dosing
- Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to use a highly effective method of contraception during the study and for at least 5 months after the last dose of study drug.
For patients on RXC004 monotherapy treatment (Arm A) the following inclusion criteria will also apply to enter the RXC004 + nivolumab treatment phase:
- Patients must have had documented RECIST1.1 defined radiological progression on RXC004 monotherapy treatment on the first scheduled scan (week 8 +/- 1 week)
- Patients must receive Cycle 1 Day 1 of combination study treatment within 28 days of the first scheduled scan (week 8 +/- 1 week).
Exclusion Criteria:
- Prior therapy with a compound of the same mechanism of action as RXC004
- Patients at higher risk of bone fractures
- Any known uncontrolled inter-current illness or persistent clinically significant toxicity related to prior anti-cancer treatment
- Patients who have any history of an active (requiring treatment) other malignancy within 2 years of study entry
- Patients with known or suspected brain metastases
- Use of anti-neoplastic agents, immunosuppressants and other investigational drugs
- Patients with a known hypersensitivity to any RXC004 excipients
- Patients with a contra-indication for denosumab treatment
- Patients who are pregnant or breast-feeding
- Use of any live or live-attenuated vaccines against infectious diseases (e.g., influenza nasal spray, varicella) within 4 weeks (28 days) of initiation of study treatment
- Patients with a mean resting corrected QTcF >470 ms, obtained from triplicate electrocardiograms performed at screening
For patients on RXC004 + nivolumab combination treatment (Arm B or Arm A RXC004 + nivolumab treatment phase):
- Patients with any contraindication to the use of nivolumab
- Patients with active or prior documented autoimmune or inflammatory disorders within the past 5 years
- Patients with active infections, including tuberculosis, hepatitis B, hepatitis C or human immunodeficiency virus
- Patients with a history of allogeneic organ transplant or active primary immunodeficiency
- Patients with a known hypersensitivity to nivolumab or any of the excipients of the product
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A: RXC004 monotherapy
Patients will receive RXC004 (2 mg once daily [QD], orally). Patients in Arm A may crossover to Arm B treatment if they have progressive disease on the first Response Evaluation Criteria in Solid Tumours, (RECIST) scan (if Arm B is open at the time of progression). |
RXC004 will be administered orally, 2 mg QD (Monotherapy); and 1.5 mg QD (Combination therapy) Dose Formulation: 0.5 mg or 1 mg capsules. Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month. Use: Prophylactic |
Experimental: Arm B: RXC004 + nivolumab
Patients will receive RXC004 (1.5 mg QD, orally) in combination with nivolumab (480 mg every 4 weeks [q4w], intravenous [IV] infusion). Arm B will be opened once a RP2D for RXC004 in combination with nivolumab is established in the phase I dose escalation study (NCT03447470). RXC004 dose to be used in combination with nivolumab will be based on data from the phase 1 study (NCT03447470). |
RXC004 will be administered orally, 2 mg QD (Monotherapy); and 1.5 mg QD (Combination therapy) Dose Formulation: 0.5 mg or 1 mg capsules. Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month. Use: Prophylactic
Nivolumab will be administered via IV infusion, 480 mg q4w.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RXC004 Monotherapy: Disease control rate (DCR) using each patients Best Overall Response (BOR) according to Response Evaluation Criteria in Solid Tumours, version 1.1 (RECIST 1.1)
Time Frame: Up to 29 months
|
To assess the anti-tumour activity of RXC004 monotherapy.
DCR is defined as the proportion of patients with a BOR of either complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks post baseline.
|
Up to 29 months
|
RXC004 + nivolumab Combination: Objective response rate (ORR) using each patients BOR according to RECIST 1.1
Time Frame: Up to 29 months
|
To assess the anti-tumour activity of RXC004 +nivolumab.
ORR is defined as the proportion of patients with a BOR of CR or PR, based on local investigator assessment, as defined in RECIST 1.1.
|
Up to 29 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum observed plasma concentration (Cmax)
Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 28 days in length)
|
To assess the pharmacokinetic (PK) of RXC004 in monotherapy and in combination with nivolumab.
|
At Cycle 0 and Cycle 1 (Each cycle is 28 days in length)
|
Time to Cmax (tmax)
Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 28 days in length)
|
To assess the PK of RXC004 in monotherapy and in combination with nivolumab.
|
At Cycle 0 and Cycle 1 (Each cycle is 28 days in length)
|
Minimum observed concentration across the dosing interval (Cmin)
Time Frame: At each treatment cycle (Each cycle is 28 days in length)
|
To assess the PK of RXC004 in monotherapy and in combination with nivolumab.
|
At each treatment cycle (Each cycle is 28 days in length)
|
Terminal rate constant (λz)
Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 28 days in length)
|
To assess the PK of RXC004 in monotherapy and in combination with nivolumab.
|
At Cycle 0 and Cycle 1 (Each cycle is 28 days in length)
|
Terminal half-life (t½)
Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 28 days in length)
|
To assess the PK of RXC004 in monotherapy and in combination with nivolumab.
|
At Cycle 0 and Cycle 1 (Each cycle is 28 days in length)
|
Area under the plasma concentration-time curve from zero to infinity (AUC0-∞)
Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 28 days in length)
|
To assess the PK of RXC004 in monotherapy and in combination with nivolumab.
|
At Cycle 0 and Cycle 1 (Each cycle is 28 days in length)
|
Total plasma clearance after oral administration (CL/F)
Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 28 days in length)
|
To assess the PK of RXC004 in monotherapy and in combination with nivolumab.
|
At Cycle 0 and Cycle 1 (Each cycle is 28 days in length)
|
Apparent volume of distribution after oral administration (Vz/F)
Time Frame: At Cycle 0 and Cycle 1 (Each cycle is 28 days in length)
|
To assess the PK of RXC004 in monotherapy and in combination with nivolumab.
|
At Cycle 0 and Cycle 1 (Each cycle is 28 days in length)
|
Percentage change in the sum of target lesions
Time Frame: Up to 29 months
|
To further assess the preliminary efficacy of RXC004 monotherapy and RXC004 + nivolumab.
Percentage change in tumour size will be derived at each visit by the percentage change from baseline in the sum of diameters of target lesions.
The best percentage change in tumour size will be the patients value representing the largest decrease (or smallest increase) from baseline in tumour size.
|
Up to 29 months
|
Duration of response (DoR)
Time Frame: Up to 29 months
|
To further assess the preliminary efficacy of RXC004 monotherapy and RXC004 + nivolumab.
The DoR will be defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression.
If a patient does not progress following a response, then their DOR will be censored at the progression free survival (PFS) censoring time.
|
Up to 29 months
|
Progression free survival (PFS)
Time Frame: From first dose of study treatment until the date of disease progression or death (Up to 29 months)
|
To further assess the preliminary efficacy of RXC004 monotherapy and RXC004 + nivolumab.
PFS is defined as the time from first dose of study treatment until the date of disease progression or death (by any cause in the absence of progression).
|
From first dose of study treatment until the date of disease progression or death (Up to 29 months)
|
RXC004 Monotherapy: ORR using investigator assessments according to RECIST 1.1
Time Frame: Up to 29 months
|
To further assess the preliminary efficacy of RXC004 monotherapy.
ORR is defined as the proportion of patients with a BOR of CR or PR, based on local investigator assessment, as defined in RECIST 1.1.
|
Up to 29 months
|
RXC004 + nivolumab Combination: DCR using investigator assessments according to RECIST 1.1
Time Frame: Up to 29 months
|
To further assess the preliminary efficacy of RXC004 + nivolumab.
DCR is defined as the proportion of patients with a BOR of either CR, PR or SD for at least 16 weeks post baseline.
|
Up to 29 months
|
Overall survival (OS)
Time Frame: Up to 29 months
|
To further assess the preliminary efficacy of RXC004 monotherapy and RXC004 + nivolumab.
OS is defined as the time from first day of study treatment until death due to any cause.
|
Up to 29 months
|
Number of patients with adverse events (AEs)
Time Frame: From time of signature of informed consent form throughout the treatment period and until 30 days after the last dose of RXC004 (for RXC004 monotherapy only) or 90 days after the last dose of Nivolumab (for RXC004 + nivolumab) (up to 29 months)
|
To assess the safety and tolerability profile of RXC004 monotherapy and RXC004 + nivolumab combination
|
From time of signature of informed consent form throughout the treatment period and until 30 days after the last dose of RXC004 (for RXC004 monotherapy only) or 90 days after the last dose of Nivolumab (for RXC004 + nivolumab) (up to 29 months)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Bone Density Conservation Agents
- Immune Checkpoint Inhibitors
- Nivolumab
- Denosumab
Other Study ID Numbers
- RXC004/0002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on RXC004
-
Redx Pharma PlcActive, not recruitingCancer | Solid TumorUnited Kingdom
-
Redx Pharma PlcMerck Sharp & Dohme LLCCompletedAdvanced Solid TumoursUnited Kingdom, Australia